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Abstract
Background: Neutrophil to lymphocyte ratio (NLR) has been proposed to predict prognosis of hepatocellular carcinoma
(HCC). However, the cut-off values are empirical. We determined the optimal cut-off value to predict HCC recurrence after
liver transplantation (LT) and further established a scoring model based on NLR.
Methodology/Principal Findings: We analyzed the outcome of 101 HBV-associated HCC patients undergoing LT.
Preoperative risk factors for tumor recurrence were evaluated by univariate analysis. By using ROC analysis, NLR$3 was
considered elevated. The disease-free survival (DFS) and overall survival (OS) for patients with high NLR was significantly
worse than that for patients with normal NLR (the 5-year DFS and OS of 28.5% and 19.5% vs. 64.9% and 61.8%, respectively;
P,0.001). Univariate analysis revealed that tumor size .5 cm, tumor number .3, macrovascular invasion, AFP$400 mg/L,
NLR$3, and HBV-DNA level .5 log10 copies/mL were preoperative predictors of DFS. Cox regression analysis showed
macrovascular invasion, tumor number, and high NLR were independent prognostic factors. We then established a
preoperative prognostic score based on multivariate analysis. Each factor was given a score of 1. Area under the ROC curve
of the score was 0.781. All nine patients with score 3 developed recurrence within 6 months after LT. Of 71 patients without
vascular invasion, three patients with both tumor number .3 and NLR$3 developed recurrence within 14 months after LT
while the 5-year DFS and OS for patients with a score of 0 or 1 were 68.1% and 62.8%, respectively.
Conclusions/Significance: Preoperative elevated NLR significantly increases the risk of recurrence in patients underwent LT
for HCC. Patients with both NLR$3 and tumor number .3 are not a good indication for LT. Our score model may aid in the
selection of patients that would most benefit from transplantation for HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent
cancers in the world, particularly in China. Chronic hepatitis B
virus (HBV) infection is the leading risk factor for HCC in China.
Liver transplantation (LT) appears to be an ideal treatment for
unresectable HCC, which accounts for about 40% of the
indications for LT in China [1]. In the absence of metastases
and macroscopic vascular invasion, LT is the best available
curative treatment option for patients with HCC on cirrhosis,
since it not only removes the tumor completely but also effectively
treats the underlying liver disease. However, before the introduc-
tion of Milan criteria in 1996 (single nodule #5 cm or two to three
nodules #3 cm) [2], survival after transplantation was disappoint-
ing due to high rate of HCC recurrence. Milan criteria have
significantly improved the outcome of LT for HCC and have been
adopted by the United Network for Organ Sharing (UNOS) to
guide patient selection. Many transplant centers confirmed the
prognostic value of Milan criteria and established LT as therapy
for HCC patients with cirrhosis [3–6]. However, the favorable
outcomes have raised the question of whether selection criteria
should be expanded. Over the last 10 years, expanded criteria
have been most thoroughly investigated in an attempt to select
suitable candidates beyond Milan criteria [3,4,7–9]. However,
both Milan and the University of California San Francisco (UCSF)
criteria (single nodule #6.5 cm, or two to three nodules with the
largest nodule #4.5 cm and the total tumor burden #8 cm) solely
rely on preoperative imaging findings including tumor number,
size, and macrovascular invasion. Unfortunately, inaccuracy of
radiological imaging remains a problem, particularly in cirrhosis
[10]. Furthermore, radiological imaging can not detect microvas-
cular invasion which has been associated with an increased risk of
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for vascular invasion and poor differentiation [11], there are at
least two reasons to explain why about 20% of patients who meet
Milan criteria still develop tumor recurrence after LT. The first
one is the inadequacy of preoperative imaging studies in assessing
vascular invasion and tumor grade. Second, a proportion of
patients tend to have some types of tumors which are more
aggressive than others although the size of tumor was small. In
addition, a proportion of patients with large tumors can achieved
excellent outcomes after LT. Therefore, to identify the risk factors
for recurrence is very important to limit or expand the indications
for LT.
Numerous clinical and experimental data have widely devel-
oped the concept that inflammation is a critical component of
tumor progression [12,13]. It is now accepted that the tumor
microenvironment contributions to the development of angiogen-
esis. Several inflammatory markers such as C reactive protein have
been suggested as surrogate markers for HCC [14]. One such a
simple and effective marker of inflammation that has been linked
with several gastroenterological malignancies is the neutrophil-
lymphocyte ratio (NLR). An elevated NLR has been shown to be
an indictor of poor outcome in patients undergoing hepatic
resection for colorectal liver metastasis [15,16], and curative
resection for HCC [17]. More recently, two studies have
demonstrated the efficacy of the NLR in predicting outcome in
patients undergoing LT for HCC [18,19]. Elevated NLR
significantly increases the risk for tumor recurrence after LT.
However, in above all these studies, the cut-off value for NLR of 5
has been set empirically. The number of patients in these studies
who had NLR more than 5 was small.
The aim of this study was to determine the optimal cut-off value
for preoperative NLR in HCC patients undergoing LT and
evaluate whether the new cut-off point for NLR correlates with
tumor recurrence. Furthermore, we established a simple preop-
erative prognostic score model that may aid in the selection of
patients that would most benefit from transplantation for HCC.
Methods
Patient selection
One hundred and one HBV-associated HCC patients treated
with LT in our hospital (Third Affiliated Hospital, Sun Yat-sen
University, Guangdong, China) during the 6-year period from
October 2003 to June 2009 were enrolled in this study.
Demographic, clinical, and laboratory data, including patient
age, gender, white cell and differential counts within 7 days
before surgery, serum alpha-fetoprotein (AFP) level, preoperative
imaging data based on abdominal computed tomography or
magnetic resonance imaging (tumor size, number, and macro-
vascular invasion), the history of pretransplant tumor therapy,
HBV infection, HBV-DNA level, and explant pathology were
recorded. Pretransplant tumor therapies included radiofrequen-
cy ablation, liver resection, ethanol ablation, transarterial
chemoembolization, local radiotherapy and systemic chemother-
apy. NLR was defined as the absolute neutrophil count divided
by the absolute lymphocyte count. Final diagnosis of HCC was
made by pathological examination of the explanted liver. The
eligibility criteria for the patients studied are as follows: (a) all
patients were HBV infected and none of them were hepatitis C
virus-positive; (b) all patients were adults (more than 18 years of
age); (c) complete clinical and laboratory data such as AFP level,
tumor size, and tumor number were available. (d) any patients
missing blood results within 7 days before surgery or missing
preoperative imaging data within 1 month before surgery were
excluded; (e) any patients demonstrating signs of preoperative
sepsis were excluded; (f) none of the patients occurred
gastrointestinal hemorrhage, undergoing pretransplant tumor
therapy, or given hematopoietic agents such as G-CSF within 1
month before surgery as these conditions can result in a falsely
elevated NLR; (g) any patients on high-dose steroids before
transplantation were excluded; and (h) patients had no HCC on
pathology or no any follow-up data were also excluded. This
study was approved by the Institutional Review Board of Key
Lab of Liver Disease Research in Guangdong Province.
Informed written consent was obtained according to the
Declaration of Helsinki.
Surgery and postoperative management
Liver transplants are performed using standard techniques
without the use of venovenous bypass. The piggyback’s technique
with suprahepatic venacavaplasty of retrohepatic cava extention
for LT was performed in most patients. Generally, our transplant
center’s postoperative immunosuppression regimen consisted of
calcineurin inhibitors and steroids. Steroids were discontinued
within 3 months.
Follow-up
After LT, patients were regularly followed up at the outpatient
clinics. Abdominal and chest CT were monitored every 3 months
in the first two postoperative years, followed by every 6 months in
the third year. AFP measurement is performed every month in the
first year and then every 3 months for the next two years. In the
following years, an annual abdominal CT scan was performed.
CT or MR imaging of the abdomen pelvis, chest and bone scan
was monitored to define suspicious lesions demonstrated on CT or
raised AFP level.
Statistical analysis
SPSS for Windows program (version 13.0) and MedCalc
statistical software v11.3.0.0 were used to analyze the data.
Patients were censored at last follow-up if still alive or lost to
follow-up. A suitable cut-off value for elevated NLR was selected
using the receiver operating characteristic (ROC) curve analysis.
The independent samples t test, and Pearson’s chi-square (x
2)t e s t
were used to analyze differences in clinicopathological features
between patients with high and normal NLR. The clinicopath-
ologic factors that were significant differences between patients
with high and normal NLR were entered into a stepwise forward
logistic regression model to determine their independent risk
factors. Survival curves were determined by the Kaplan–Meier
method. Potential predictors of patient outcomes and disease-free
survival were entered into univariate Kaplan–Meier models and
tested by the log-rank statistic. Preoperative clinicopathologic
factors that had significant impact on disease-free survival in the
univariate analysis were entered into a multivariate Cox
regression model (stepwise forward method) to determine their
independent effect. A preoperative prognostic score model was
established to predict tumor recurrence based on preoperative
factors that were significant on multivariate analysis. Univariate
Cox proportional hazards regression analysis was applied to
estimate the hazard ratio for the risk of tumor recurrence. By
using MedCalc statistical software, the area under the ROC
curve (AUC) for the score model was measured and then
compared with the Milan, UCSF, and HangZhou criteria (tumor
,8 cm, or $8 cm but with well differentiation and serum
AFP#400 ng/mL) [20]. Variables with P,0.05 were considered
statistically significant.
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Patient demographics and outcomes
Ninety-two patients (91.1%) were men and 9 (8.9%) women.
The mean age of patients at transplant was 48.4 years (range: 27–
72 years). Thirty-five patients (34.7%) received pretransplant
tumor therapy. Fifty-one patients died during follow-up and 4
died within one month post-transplantation. Of 42 patients
(41.2%) developed tumor recurrence, 28 (66.7%) developed
recurrence within 1 year and 38 (90.5%) developed recurrence
within 2 years after LT. Mean follow-up time was 2.85 years
(range: 0.38–6.22 years) with 7 patients lost to follow-up. The 1-,
3-, and 5-year (yr) overall survival (OS) and disease-free survival
(DFS) rates for all patients included in this study were 80.2%,
55.4%, and 47.6% and 70.7%, 55.6%, and 53.6%, respectively
(Figure S1).
An optimal cut-off value for elevated NLR
By using ROC curve analysis, we determined the optimal
cut-off value for elevated NLR. The area under the receiver
operating characteristic curves was 0.667 with a 95%
confidence interval (95% CI) for the area being between
0.557 and 0.777 (Figure S2). A cut-off value of 2.48 presented a
sensitivity of 59.5% and a specificity of 71.2%. When the cut-
off point was increased to 2.99, the sensitivity was 50% and the
specificity was 79.7%. Therefore, the cut-off value of 3.0 was
used in this study.
Risk factors for recurrence of hepatocellular carcinoma
after LT
Univariate analysis of factors affecting disease-free survival was
shown in Table 1. More than three tumor nodules, size of largest
tumor .5 cm, macrovascular invasion, AFP $400 ng/mL,
NLR$3, and HBV-DNA level .5 log10 copies/mL were all
preoperative prognostic predictors of poorer DFS. The NLR was
elevated at $3 in 34 patients (33.3%). A significant difference in
DFS existed between patients with normal and elevated NLR. The
5-yr DFS of 64.9% in patients with a normal NLR compared with
28.5% in patients with an elevated NLR, respectively, P,0.001,
Figure 1A). Of 30 patients with macrovascular invasion, 3 died
within 1 month after transplantation; 2 died from biliary infection
and multiple organ dysfunction syndrome 5 and 7 months after
transplantation, respectively; 4 had no tumor recurrence during 5
years of follow-up; tumor recurrence were detected in all the other
21 patients during 18 months of follow-up. Of 4 patients without
tumor recurrence, 3 had no macroscopic tumor thrombus in the
explant liver and histopathologic analysis revealed no evidence of
microvascular invasion. Of 71 patients without macrovascular
invasion on preoperative imaging, 16 patients with high NLR had
slightly lower DFS than patients with normal NLR but no
Table 1. Preoperative factors affecting disease-free survival and overall survival.
Category Subcategory (n) Disease-free survival Overall survival
5 years
Univariate
analysis
Multivariate
analysis HR (95%CI) 5 years
Univariate
analysis
Multivariate
analysis HR (95%CI)
Gender Male (92) 52.0% 0.271 – 46.4% 0.360 –
Female (9) 72.9% 58.3%
Age ,60 years (87) 72.9% 0.189 – 46.7% 0.703 –
$60 years (14) 63.5% 50.0%
Preoperative
tumor therapy
Yes (35) 63.5% 0.189 – 42.2% 0.171 –
No (66) 47.9% 57.8%
Size of largest tumor #3 cm (26) 69.9% 0.002 NS 66.7% ,0.001 NS
#5 cm (34) 61.5% 62.8%
#8 cm (14) 40.8% 27.8%
.8 cm (27) 31.1% 20.0%
Tumor numbers #3 (68) 67.9% ,0.001 ,0.001 4.117
(2.087–8.123)
58.0% ,0.001 ,0.001 3.013
(1.644–5.524)
.3 (33) 24.5% 26.4%
Vascular invasion No (71) 66.8% ,0.001 ,0.001 3.908
(1.965–7.772)
61.6% ,0.001 ,0.001 3.253
(1.734–7.772)
Yes (30) 17.2% 15.0%
AFP ,400 ng/mL (61) 65.9% ,0.001 NS 62.6% ,0.001 NS
$400 ng/mL (40) 32.1% 24.6%
NLR ,3 (68) 64.9% ,0.001 ,0.001 3.665
(1.799–7.466)
61.8% ,0.001 ,0.001 2.654
(1.419–4.964)
$3 (33) 28.5% 19.5%
HBV-DNA level .
5 log10 copies/mL
No (88) 60.8% 0.016 NS 51.9% 0.021 NS
Yes (13) 10.4% 19.2%
Abbreviation: CI, confidence interval; HR, hazard ratio; NS, not significant.
doi:10.1371/journal.pone.0025295.t001
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53.0%, respectively, P=0.106, Figure S3A).
Multivariate regression analysis was performed on all 6
preoperative factors that were statistically significant difference
in DFS by univariate analysis. The results revealed that the
presence of macrovascular invasion, tumor number .3, NLR $3
were the independent prognostic predictors of poor DFS (Table 1).
With regards to overall survival, there was a significant
difference in overall survival between patients with low and high
NLR (5-yr OS of 61.8% vs. 19.5%, respectively, P,0.001,
Figure 1B). Again, on multivariate analysis, the presence of
macrovascular invasion, tumor number .3, NLR$3 were the
independent prognostic predictors of overall survival (Table 1). Of
patients without macrovascular invasion, patients with high NLR
had significant lower OS than patients with normal NLR (5-yr OS
of 69.6% vs. 36.7%, respectively, P=0.037, Figure S3B).
The analysis of clinicopathologic characters in patients
with elevated NLR
The analysis of clinicopathologic characters in patients with
normal or elevated NLR is shown in Table 2. Size of largest tumor
.5 cm, macrovascular invasion, AFP$400 ng/mL, outside
Milan, outside UCSF, and outside HangZhou criteria were
significant differences between patients with normal and high
NLR based on univariate analysis. Furthermore, multivariate
logistic regression analysis using all three parameters, eg, size of
largest tumor, macrovascular invasion, and AFP, revealed that
only macrovascular invasion remained associated with high NLR
(P=0.001, relative risk=4.495, 95% CI=1.086–11.188).
Classification of patients according to NLR and the
different criteria
In this study, 36 patients (35.6%) were within Milan criteria. Of
the patients who were outside Milan, 9 and 26 were classified
within UCSF and HangZhou criteria, respectively. The DFS of
patients who were inside Milan criteria did not significantly differ
from those patients outside Milan but within UCSF criteria (log
rank test, P=0.07), and similarly, patients outside Milan but
within UCSF did not significantly differ from patients outside
UCSF but within HangZhou criteria. However, patients within
Milan had significantly better DFS than patients outside UCSF
but within HangZhou criteria (log rank test, P=0.001), and
patients outside UCSF but within HangZhou criteria had
significantly better DFS than patients outside HangZhou criteria
(log rank test, P=0.025), as shown in Figure 2A. Hangzhou
criteria significantly expand the indications for liver transplanta-
tion with acceptable rates of 5-yr DFS and OS (70.3% and 65.3%,
respectively, Figure S4).
Four patients who met Milan criteria had an elevated NLR. Of
32 patients with normal NLR and within Milan criteria, only three
patients have shown tumor recurrence within 1 year and have died
within 2 years after OLT. No tumor recurrence was found in all
the other 29 patients during follow-up. There was no significant
difference in DFS between patients with normal and high NLR of
patients who met Milan criteria. However, of the patients beyond
the criteria, a significant difference in DFS existed between
patients with normal and elevated NLR; 29 patients with a high
NLR having the 5-yr DFS of 21.5% compared with 42.2% in 36
patients with a normal NLR, respectively (P=0.015, Figure 2B).
The similar results were obtained when patients were reclassified
according to UCSF and HangZhou criteria. Of 56 patients
beyond UCSF criteria, 25 patients with a high NLR having a 5-yr
DFS of 10.7% compared with 41.2% in 31 patients with a normal
NLR (P=0.001).
A preoperative prognostic scoring model
Based on the preoperative recurrence score recently published
by Halazun et al. [18] for tumor recurrence in patients
transplanted for HCC, we established a preoperative prognostic
score model, using the 3 preoperative prognostic factors found to
be significant on multivariate analysis, namely, vascular invasion,
tumor number, and NLR. Each factor was given a score of 1 and
then patients were divided into 4 categories. Differences in DFS
stratified according to the preoperative prognostic scores are
shown in Figure 3A. The 5-yr DFS for 43 patients with a score of 0
was 81.9%, compared with 53.6% for 30 patients with a score of 1
(P=0.018). The DFS in 19 patients with a score of 2 decreased
sharply (the 1- and 2-yr survivals of 32.7% and 6.5%, respectively).
Nine patients with a score of 3 had the worst DFS of all groups. All
these patients showed tumor recurrence within 6 months and died
Figure 1. Kaplan-Meier survival curves for patients with high or normal NLR. There was a significant difference in DFS and OS between
patients with low and high NLR. The 5-yr DFS (A) and OS (B) for patients with normal or high NLR were 64.9%, 28.5%, and 61.8%, 19.5%, respectively
(both P,0.001).
doi:10.1371/journal.pone.0025295.g001
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score of 2 and 3 were 3.8 and 8.5 months, respectively, compared
with 5 years for patients with a score of 1. Patients with a score of 0
had minimal recurrence, with 36 patients (83.7%) being disease
free at 5 years. Clearly, therefore, the DFS for patients with a score
of 2 or 3 was significantly worse than that for patients with a score
of 0 or 1 (the 1- and 3-yr DFS, 23.8% and 4.8% vs. 86.0% and
71.7%, respectively, P,0.001, Figure 3B).
Of 30 patients with macrovascular invasion on preoperative
imaging, one of 3 patients with a score of 1 had no macroscopic
tumor thrombus in the explant liver and histopathologic analysis
revealed no evidence of microvascular invasion. He had no tumor
recurrence during 23 months of follow-up. The other 27 patients
had 2 or 3 scores. These results indicated that patients with a
score of 2 or 3 were not a good indication for liver transplantation
but patients with a score of 0 or 1 can achieve an acceptable
survival after LT with a 5-yr DFS and OS of 69.1%, 63.8%,
respectively.
The predictive value of the preoperative prognostic score
model, as well as the value of Milan, UCSF and HangZhou
criteria was assessed using univariate Cox proportional hazards
regression analysis (Table 3). The preoperative prognostic score
was superior to the Milan, UCSF and HangZhou criteria, with
scores of 1, 2, and 3 having hazard ratios of 2.912, 15.533, and
48.715, respectively. ROC curve analysis of the preoperative
prognostic score versus that of Milan, UCSF and HangZhou
criteria is shown in Table 4 and Figure S5 by using MedCalc
statistical software. The preoperative prognostic score was the
most accurate at predicting recurrence with the AUC of 0.781
though no statistically significant difference was observed.
Preoperative prognostic scores predict tumor recurrence
in patients without macrovascular invasion
Because patients with gross vascular invasion of the portal vein,
hepatic veins, or vena cava were not considered a good indication
for LT due to the high rate of tumor recurrence, we next analyzed
Table 2. Comparison of clinicopathological features of patients with elevated and normal NLR.
Factors NLR,3 (n=68) NLR$3 (n=33) t or x
2 P
Age (mean) 48.8 years 47.5 years 0.62 0.536
Male 61 (89.7%) 31 (93.9%) 0.108 0.743
Preoperative tumor therapy 27 (39.7%) 8 (24.2%) 2.346 0.126
Size of largest tumor .5 cm 21 (30.9%) 20 (60.6%) 8.140 0.004
Tumor numbers .3 21 (30.9%) 12 (36.4%) 0.303 0.582
Vascular invasion 13 (19.1%) 17 (51.5%) 11.168 0.001
AFP$400 ng/mL 20 (29.4%) 20 (60.6%) 9.039 0.003
HBV-DNA level .5 log10 copies/mL 9 (13.2%) 4 (12.1%) 0.000 1.000
Outside Milan criteria 36 (52.9%) 29 (87.9%) 11.823 0.001
Outside UCSF criteria 31 (45.6%) 25 (75.6%) 8.186 0.004
Outside HangZhou criteria 18 (26.5%) 21 (63.6%) 12.947 ,0.001
Abbreviation: NLR, neutrophil-lymphocyte ratio.
doi:10.1371/journal.pone.0025295.t002
Figure 2. Disease-free survival for patients classified according to NLR and the different criteria. (A) The Kaplan-Meier curves for patients
classified according to the Milan, UCSF and HangZhou criteria showed patients within Milan had significantly better DFS than patients outside UCSF
but within HangZhou criteria (log rank test, P=0.001). (B) Among patients beyond Milan criteria, a significant difference in DFS existed between
patients with normal and elevated NLR (log rank test, P=0.015).
doi:10.1371/journal.pone.0025295.g002
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vascular invasion detected by preoperative imaging. Patients were
divided into 3 categories. The results showed all 3 patients with a
score of 2 got tumor recurrence within 14 months and died within
23 months after LT while the 5-yr DFS and OS for patients with a
score of 0 and 1 were 81.4%, 74.2%, and 54.6%, 53.7%,
respectively (Figure 4A and B). The DFS and OS for patients with
a score of 2 was significantly worse than patients with a score of 1
(P,0.001 and =0.001, respectively). Of 26 patients with a score of
1, 13 patients with high NLR had slightly lower DFS rates than
patients with more than 3 tumor nodules but no statistically
significant difference was found (the 3- and 5-yr survivals, 68.4%
and 45.6% vs. 76.9% and 59.8%, respectively, P=0.756). Patients
with scores of 1 and 2 had hazard ratios of 2.615 and 31.810,
respectively. Patients with a score of 0 or 1 can achieve long-term
survival after LT with a 5-yr DFS of 69.9% and OS of 64.4%,
respectively. The preoperative prognostic score model for patients
without vascular invasion revealed the strong associations of tumor
recurrence risk with tumor numbers and high NLR with the AUC
of 0.705 with the 95% CI of 0.565–0.844. These results indicated
that patients without vascular invasion but with both elevated
NLR and more than 3 tumor nodules were also not a good
indication for LT. Our preoperative prognostic score significantly
expand the indications for liver transplantation.
Discussion
Among appropriately selected candidates, LT for HCC
provides excellent outcomes with 5-yr survival rates similar to
patients undergoing LT for liver cirrhosis without HCC. However,
about 20% of patients with Milan criteria still develop tumor
recurrence after LT [2]. There remains controversy about
expanding the criteria for selection of HCC patients for LT for
a proportion of patients with tumor burden beyond Milan criteria
may potentially benefit from LT. Lack of available liver donors is
the main restricting factor for LT and contributes to prolonged
waiting time, which is associated with increased drop out rates.
However, expansion of selection criteria increases not only the risk
of tumor recurrence, but also the need for donor organs, and
further lengthens waiting time. Early experience demonstrated
that tumor size was an important predictor of recurrence and
survival for patients undergoing LT for HCC. But the preoper-
ative tumor size can only be assessed by preoperative radiological
imaging, which underestimates tumor stage in about 30% of cases,
especially in patients with tumors beyond Milan criteria [8]. For all
these reasons, there is an urgent need to develop new non-invasive
Figure 3. Disease-free survival for patients classified according to the preoperative prognostic score. (A) The Kaplan-Meier curves
showed there was a significant difference in DFS among four groups of patients with score 0 to 3. (B) A significant difference in DFS existed when
patients were reclassified into two groups (score 0 or 1, and 2 or 3).
doi:10.1371/journal.pone.0025295.g003
Table 3. Univariate Cox regression analysis of preoperative
score model as well as Milan, UCSF and HangZhou criteria.
P Hazard Ratio 95% CI
Preoperative
prognostic score=0
—— —
Preoperative
prognostic score=1
0.023 2.912 1.161–7.305
Preoperative
prognostic score=2
,0.001 15.533 6.097–39.568
Preoperative
prognostic score=3
,0.001 48.715 13.974–169.825
Milan criteria ,0.001 8.528 3.035–23.960
UCSF criteria ,0.001 6.615 2.926–14.956
HangZhou criteria ,0.001 5.240 2.772–9.903
doi:10.1371/journal.pone.0025295.t003
Table 4. ROC curve analysis of preoperative prognostic score
versus Milan, UCSF and HangZhou criteria.
AUC 95% CI
Milan criteria 0.724 0.624–0.823
UCSF criteria 0.739 0.640–0.838
HangZhou criteria 0.699 0.593–0.806
Preoperative prognostic score 0.781 0.688–0.875
Abbreviation: AUC, the area under the ROC curve; CI, confidence interval; ROC,
the receiver operating characteristic.
doi:10.1371/journal.pone.0025295.t004
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hepatic resection or transplantation.
Consistent lines of evidence have suggested that there is a close
relationship between the development of cancer and inflamma-
tion. Inflammation contributes to the development of at least 15%
of all cancers, in particular, for the digestive system cancers [21].
Patients with HBV infections experience chronic inflammation
which increases risk of liver cancer. Neutrophil to lymphocyte
ratio (NLR), a simple and effective marker of inflammation, is
easily calculated from routinely available data. During the past five
years, some studies have demonstrated that an elevated NLR is an
important prognostic factor in patients with a variety of digestive
system malignancies including esophageal cancer [22], gastric
cancer [23,24], colorectal cancer [25,26], colorectal liver metas-
tases [15,16,27], pancreatic adenocarcinoma [28], intrahepatic
cholangiocarcinoma [29], and HCC [17,18]. However, in all these
studies, the cut-off value for NLR of 5 has been set empirically
except for one study of gastric cancer with the cut-off level of 4
based on Kaplan-Meier analysis. To our knowledge, this is the first
report discussing the appropriate cut-off point of NLR in
predicting prognosis in patients with HCC. First, we determined
the optimal cut-off point for preoperative NLR to predict HCC
patients with high risk of tumor recurrence after LT. By using
ROC curve analysis, we found that the cut-off value of 3.0 had a
relatively high specificity. Although patients with NLR values
between 3.0 and 5.0 were classified as having an elevated NLR
based on our new cut-off value, our results showed that patients
with NLR,3 showed significantly better DFS and better OS than
those of patients with NLR$3. The results of multivariate
regression analysis revealed that NLR$3 was the independent
prognostic predictor of poor DFS. This is consistent with the
above studies. Although the relationship between elevated NLR
and increased risk for early recurrence and poor prognosis is
largely unclear, there are several possible mechanisms explaining
the predictive role of preoperative elevated NLR. The systemic
and local inflammatory response to tumor may provide a favorable
environment for tumor invasion and metastases [13]. Further-
more, except for chronic inflammation caused by HBV and tumor
itself, high expressions of granulocyte colony-stimulating factor in
tumor tissue and macrophage colony-stimulating factor in
peritumoral tissue are also associated with the elevated circulating
neutrophils and poor prognosis [30–32]. Circulating elevated
levels of vascular endothelial growth factor secreted mainly by
circulating neutrophils have been associated with increased risk of
recurrence in patients with HCC [33]. On the other hand,
reduced lymphocyte infiltration, reflecting an impaired host
immune response, has been shown to predict recurrence in
HCC patients following LT [34]. NLR reflects an immune
microenvironment that both favors tumor vascular invasion and
suppresses the host immune surveillance. In addition, NLR can
not only predict tumor recurrence but also be used for diagnosis of
tumor. A recent study has showed that NLR can be a useful tool
for preoperative diagnosis in patients with uterine sarcomas [35].
Although univariate analysis in this study showed that tumor
size, AFP level, and HBV-DNA level were preoperative prognostic
predictors of poorer DFS, none of these factors were identified as
independent predictors on multivariate analysis. However, this
result did not mean that these factors were not associated with
recurrence. In fact, previous studies have showed that tumor size
.3 cm on imaging is an independent predictor of microvascular
invasion [36,37]. Our results showed a significant association
between the elevated NLR and the tumor size, AFP level, and
macrovascular invasion. Taken together, these results indicated
that preoperative elevated NLR can indirectly reflect tumor
burden, malignancy, invasion, and metastasis.
We found that more than 3 tumor nodules were an independent
predictor of recurrence. The result was concomitant with some
studies [37,38] but not the others [20,39,40]. Multiple tumor
nodules can be categorized into two types: multifocal occurrence
and intrahepatic metastasis. HCC patient with intrahepatic
metastasis has a poorer prognosis than those with multifocal
occurrence. Although fast developed imaging techniques can
detect small intrahepatic metastasis, we can not accurately
distinguish intrahepatic metastasis from multifocal occurrence
based on preoperative imaging. However, in our current study
including 27 patients with tumor size .8 cm, we notified that
multiple small satellite nodules seemed to surround a large main
tumor. The different background of hepatitis may also partly
explain that our results were different from that of other
publications from Japan or Europe. HCC patients with HCV-
associated cirrhosis have a higher incidence of multifocal
occurrence than patients with HBV-related cirrhosis [41].
Figure 4. The prognostic value of the preoperative prognostic score model for patients without vascular invasion. The Kaplan-Meier
curves showed there was a significant difference in DFS (A) and OS (B) between patients with a score of 2 and patients with a score of 0 or 1.
doi:10.1371/journal.pone.0025295.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25295Based on multivariate analysis, we have therefore established a
simple preoperative prognostic score model that is superior to the
Milan, UCSF and HangZhou criteria at predicting recurrence,
with an AUC of 0.781. All patients with a score of 3 showed tumor
recurrence within 6 months after LT. The median DFS for
patients with a score of 2 and 3 were 3.8 and 8.5 months,
respectively. Clearly, LT for these patients is futile. As for patients
without macrovascular invasion on radiological findings, all 3
patients with scores of 2 (both NLR$3 and tumor nodules .3),
who got recurrence within 14 months after LT, had hazard ratios
of 31.810 with an AUC of 0.705. Whereas patients with a score of
0 or 1 may achieve similar survival outcomes as patients within
HangZhou criteria, but including more patients (69 and 62
patients, respectively). These results indicated that patients without
vascular invasion but with both elevated NLR and more than 3
tumor nodules were also not a good indication for LT. A similar
study has demonstrated that a scoring model based on NLR before
treatment offers a very informative method for predicting
prognosis of gastric cancer [42].
Although we demonstrated the prognostic value of NLR in
predicting recurrence, it would not be appropriate to conclude
that LT should not be considered only because preoperative NLR
is high. There are many other factors affecting NLR, such as an
acute undetected infection, which affects the accuracy of
prognostic prediction. In addition, all patients enrolled had a
history of hepatitis B, which may bias the study since hepatitis C is
the most common predisposing factor to HCC development in
Western countries and Japan. In addition, our study was limited
by the retrospective nature of the analysis and the relatively small
number of patients was included in the report. Clearly, further
prospective studies are needed to confirm and update our
preoperative prognostic score model for the prediction of post-
transplant tumor recurrence in patients with HCC.
Supporting Information
Figure S1 Disease-free survival (A) and overall survival (B) rates
for all patients included in this study.
(TIF)
Figure S2 Receiver operating characteristic curve for NLR
predicting tumor recurrence.
(TIF)
Figure S3 Kaplan-Meier survival curves for patients without
macrovascular invasion and with high or normal NLR. Of patients
without macrovascular invasion, the impact of high NLR on DFS
was not statistically significant (A), but patients with high NLR had
significant lower OS than patients with normal NLR (B).
(TIF)
Figure S4 Kaplan-Meier DFS (A) and OS (B) curves for patients
with or beyond Hangzhou criteria.
(TIF)
Figure S5 Receiver operating characteristic curve for the
different criteria predicting tumor recurrence.
(TIF)
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